UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

Amarin Corporation plc
(Name of Issuer)
 
Ordinary Shares, par value 50 pence per share
(Title of Class of Securities)
 
023111206
(CUSIP Number)
 
Mark DiPaolo
Senior Partner, General Counsel
Sarissa Capital Management LP
660 Steamboat Road
Greenwich, CT 06830
203-302-2330
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
January 10, 2023
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






CUSIP No. 023111206
Page 2 of 9 Pages
SCHEDULE 13D


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Sarissa Capital Management LP
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐
3
SEC USE ONLY
 
 
4
SOURCE OF FUNDS

WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
 
 ☐
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER

0
8
SHARED VOTING POWER

25,210,000
9
SOLE DISPOSITIVE POWER

0
10
SHARED DISPOSITIVE POWER

25,210,000
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

25,210,000
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:


 ☐
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

6.24%
14
TYPE OF REPORTING PERSON
 
PN




CUSIP No. 023111206
Page 3 of 9 Pages
SCHEDULE 13D


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Alexander J. Denner, Ph.D.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐
3
SEC USE ONLY
 
 
4
SOURCE OF FUNDS

AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
 
 ☐
6
CITIZENSHIP OR PLACE OF ORGANIZATION

United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER

0
8
SHARED VOTING POWER

25,210,000
9
SOLE DISPOSITIVE POWER

0
10
SHARED DISPOSITIVE POWER

25,210,000
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

25,210,000
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:


 ☐
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

6.24%
14
TYPE OF REPORTING PERSON
 
IN


CUSIP No. 023111206
Page 4 of 9 Pages
SCHEDULE 13D


1
NAME OF REPORTING PERSON OR
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Louis Sterling III
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐
(b)  ☐
3
SEC USE ONLY
 
 
4
SOURCE OF FUNDS

PF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
 
 ☐
6
CITIZENSHIP OR PLACE OF ORGANIZATION

United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER

117,772
8
SHARED VOTING POWER

0
9
SOLE DISPOSITIVE POWER

117,772
10
SHARED DISPOSITIVE POWER

0
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

117,772
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:


 ☐
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

Less than 1%
14
TYPE OF REPORTING PERSON
 
IN


CUSIP No. 023111206
Page 5 of 9 Pages
SCHEDULE 13D


This Amendment No. 4 to Schedule 13D (“Amendment No. 4”) relates to American Depositary Shares (“ADS(s)”), each ADS representing one ordinary share, par value 50 pence per share (the “Ordinary Shares”), issued by Amarin Corporation plc, a company incorporated under the laws of England and Wales (the “Issuer”), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2022 (the “Initial Schedule 13D”), as amended by Amendment No. 1 to Schedule 13D filed on June 3, 2022, Amendment No. 2 to Schedule 13D filed on June 16, 2022, and Amendment No. 3 to Schedule 13D filed on October 11, 2022 (the Initial Schedule 13D as so amended, the “Schedule 13D”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
This Amendment No. 1 is being filed by Sarissa Capital Management LP, a Delaware limited partnership (“Sarissa Capital”) and Alexander J. Denner, Ph.D., a citizen of the United States of America (“Dr. Denner” and together with Sarissa Capital, the “Sarissa Reporting Persons”) and Louis Sterling III (“Mr. Sterling” and, together with the Sarissa Reporting Persons and Mr. Sterling, the “Reporting Persons”).
This Amendment No. 4 is being filed to amend Item 2, Item 3, Item 4, Item 5, Item 6 and Item 7 as follows:
Item 2.  Identity and Background. Item 2 of the Schedule 13D is hereby amended to include the following:
 
(a)
This Schedule 13D is being filed by each of the Reporting Persons.
     
 
(b)
The principal business address of Mr. Sterling is 133 Gale Drive, Beverly Hills, CA 90211.
     
 
(c)
Mr. Sterling is a private investor.
     
 
(d)
Mr. Sterling has not, during the past five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
     
 
(e)
Mr. Sterling has not, during the past five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or a finding of any violation with respect to such laws.
     
 
(f)
Mr. Sterling is a citizen of the United States of America.
Item 3.  Source or Amount of Funds or Other Consideration. Item 3 of the Schedule 13D is hereby amended to include the following:
The Sarissa Reporting Persons may be deemed to be the beneficial owner of, in the aggregate, 25,210,000 Shares. The aggregate purchase price of the Shares purchased by the Sarissa Reporting Persons as reported in Item 5(c) of this Amendment 4 is approximately $1,423,407. The source of funding for these purchases was the general working capital of the respective purchasers.
Mr. Sterling may be deemed to be the beneficial owner of 117,772 Shares. The aggregate purchase price of these Shares is approximately $378,752. The source of funding for these purchases was Mr. Sterling’s personal funds.

CUSIP No. 023111206
 Page 6 of 9 Pages
SCHEDULE 13D

Item 4.  Purpose of Transaction. Item 4 of the Schedule 13D is hereby amended to include the following:
On January 10, 2023, certain of the Sarissa Reporting Persons submitted a requisition notice to the Issuer to call a general meeting of shareholders to, among other things, appoint Patrice Bonfiglio, Paul Cohen, M.D., Mark DiPaolo Esq., Keith Horn, Odysseas Kostas M.D., Louis Sterling III and Diane Sullivan (collectively, the “Sarissa Nominees”) as directors of the Issuer. The requisition also included a proposal to remove Per Wold-Olsen as a director of the Issuer.  A copy of the requisition notice is attached hereto as Exhibit 4 and is incorporated herein in its entirety. Sarissa Capital also issued a press release announcing the submission of the requisition. A copy of the press release is attached as Exhibit 5 hereto.
Mr. Sterling acquired Shares for investment purposes. Mr. Sterling has agreed to serve as one of the Sarissa Nominees for election to the Issuer’s Board at the meeting of stockholders requisitioned by Sarissa Capital.
Item 5.  Interest in Securities of the Issuer. Item 5 of the Schedule 13D is hereby amended and restated as follows:
(a)
The Sarissa Reporting Persons may be deemed to beneficially own, in the aggregate, 25,210,000 Shares representing approximately 6.24% of the outstanding Shares (the “Sarissa Shares”). Mr. Sterling may be deemed to beneficially own, in the aggregate, 117,772 Shares representing approximately 0.03% of the outstanding Shares (the “Sterling Shares”), including call options representing 53,500 Shares (as further described in Item 6). Percentages of the outstanding Shares are based upon the 403,828,955 Shares outstanding as of October 21, 2022, including 383,347,128 ADSs, and 20,481,827 Ordinary Shares, as set forth in the Form 10-Q of the Issuer filed with the SEC on October 27, 2022.
(b)
For purposes of this Schedule 13D:
 
All of the Shares which the Sarissa Reporting Persons may be deemed to beneficially own are held directly by the Sarissa Funds. Sarissa Capital, as the investment advisor to the Sarissa Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the Shares held directly by the Sarissa Funds. By virtue of his position as the Chief Investment Officer of Sarissa Capital and by virtue of his control of the ultimate general partner of Sarissa Capital, Dr. Denner may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the Shares held directly by the Sarissa Funds.
 
Mr. Sterling has sole power to vote and dispose the Sterling Shares.
 
The Sarissa Reporting Persons and Mr. Sterling may be deemed to have formed a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended, and may be deemed to beneficially own, in the aggregate, 25,327,772 Shares representing approximately 6.27% of the outstanding Shares. The Sarissa Reporting Persons disclaim beneficial ownership of the Sterling Shares. Mr. Sterling disclaims beneficial ownership of the Sarissa Shares.
(c)
On December 2, 2022, the Sarissa Funds acquired 40,000 Shares at $1.21 per Share in open market transactions, for an aggregate purchase price of $48,744.
 
On December 5, 2022, the Sarissa Funds acquired 75,000 Shares at $1.17 per Share in open market transactions, for an aggregate purchase price of approximately $88,388.
 
On December 6, 2022, the Sarissa Funds acquired 470,000 and 76,450 Shares at $1.17 and $1.16 per Share in open market transactions, for an aggregate purchase price of approximately $643,195.
 
On December 7, 2022, the Sarissa Funds acquired 250,550 Shares at $1.17 per Share in open market transactions, for an aggregate purchase price of approximately $295,053.
 
On December 8, 2022, the Sarissa Funds acquired 30,000 and 75,000 Shares at $1.16 and $1.15 per Share in open market transactions, for an aggregate purchase price of $122,049.
 
On December 28, 2022, the Sarissa Funds acquired 90,000 Shares at $1.16 per Share in open market transactions, for an aggregate purchase price of $105,543.
 
On January 3, 2023, the Sarissa Funds acquired 103,000 Shares at $1.16 per Share in open market transactions, for an aggregate purchase price of approximately $120,436.


CUSIP No. 023111206
 Page 7 of 9 Pages
SCHEDULE 13D
Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. Item 6 of the Schedule 13D is hereby amended and restated as follows:
Derivative Transactions
The Reporting Persons may, from time to time, enter into and dispose of cash-settled equity swap, stock-settled equity swap, option or other derivative transactions with one or more counterparties that are based upon the value of the Shares, which transactions may be significant in amount. The profit, loss and/or return on such contracts may be wholly or partially dependent on the market value of the Shares. Mr. Sterling currently has purchased out-of-the-money call options representing 53,500 Shares through such contracts, which Shares are reflected in the amounts reported in Item 5.
Joint Filing Agreement
On January 10, 2023, the Sarissa Capital, Dr. Denner and Mr. Sterling entered into a Joint Filing Agreement pursuant to which, among other things, the parties agreed to the joint filing on behalf of each of them of statements on Schedule 13D, and any amendments thereto, with respect to the securities of the Issuer to the extent required by applicable law. The Joint Filing Agreement is attached hereto as Exhibit 6 and is incorporated herein by reference.
Item 7.  Material to Be Filed as Exhibits. Item 7 of the Schedule 13D is hereby amended to include the following:
Exhibit 4 – Requisition Notice, January 10, 2023
Exhibit 5 – Press Release, January 10, 2023
Exhibit 6 – Joint Filing Agreement of the Reporting Persons
Exhibit 7 – Power of Attorney Granted by Louis Sterling III in favor of Mark DiPaolo and Patrice Bonfiglio, January 10, 2023



CUSIP No. 023111206
 Page 8 of 9 Pages
SCHEDULE 13D
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 10, 2023

SARISSA CAPITAL MANAGEMENT LP


By: /s/ Mark DiPaolo _______________
 Name: Mark DiPaolo
 Title: Senior Partner, General Counsel


/s/ Alexander J. Denner                                                                
Alexander J. Denner


/s/ Louis Sterling III                                                
Louis Sterling III

CUSIP No. 023111206
 Page 9 of 9 Pages
SCHEDULE 13D


INDEX TO EXHIBITS

Exhibit 1 – Joint Filing Agreement of the Reporting Persons*
Exhibit 2 – Press Release, June 15, 2022*
Exhibit 3 – Press Release, October 11, 2022*
Exhibit 4 – Requisition Notice, January 10, 2023
Exhibit 5 – Press Release, January 10, 2023
Exhibit 6 – Joint Filing Agreement of the Reporting Persons
Exhibit 7 – Power of Attorney Granted by Louis Sterling III in favor of Mark DiPaolo and Patrice Bonfiglio, January 10, 2023

*  Previously filed.

EXHIBIT 4


The Directors
Amarin Corporation plc

77 Sir John Rogerson’s Quay
Block C
Grand Canal Docklands
Dublin 2, Ireland

January 10, 2023
Dear Sirs
Request to convene a general meeting of Amarin Corporation plc (“Company”) and special notice of a resolution to remove a director of the Company, if applicable
Pursuant to section 303 Companies Act 2006 (the “Companies Act”), the undersigned, being an authorized representative of the holders of not less than 5% of the paid-up share capital of the Company, as set forth on Appendix A attached hereto, which at the date of this requisition carries the right to vote at general meetings of the Company, requires you to call a general meeting of the Company not later than 21 days after you receive this requisition.
The business to be dealt with at the general meeting is to consider the proposals that (i) Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III, and Diane E. Sullivan each be appointed as a director of the Company, (ii) Per Wold-Olsen be removed from office as a director of the Company, and (iii) in the event any director is appointed after the Company’s receipt of this requisition, each such director be removed from office as a director of the Company.
At the general meeting it is intended to consider and, if thought fit, pass the following resolutions, which are being proposed as ordinary resolutions, and we give special notice pursuant to sections 168(2) and 312(1) of the Companies Act in relation to the resolutions to remove a director under section 168 of the Companies:
Ordinary resolution:
1.
“THAT Per Wold-Olsen be removed from office as a director of the Company with immediate effect.”
2.
“THAT in the event any director is appointed after the Company’s receipt of the general meeting requisition notice dated January 10, 2023, and prior to the general meeting, each such director be removed from office as a director of the Company with immediate effect.”
3.
“THAT each of Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III, and Diane E. Sullivan, having consented to act, be appointed as an additional director of the Company with immediate effect.”
The holders intend to solicit the holders of shares representing at least 67% of the voting power of shares entitled to vote on the election of directors in support of the foregoing director nominees.
Attached hereto as Appendix B are signed notices by each Director Nominee of their willingness to be elected as a director of the Company.



Signed by:
/s/ Mark DiPaolo
……………………………………….
Mark DiPaolo, as an authorized person




APPENDIX A
Members













APPENDIX B
Notices of willingness to be elected as a director of the Company












EXHIBIT 5

SARISSA CAPITAL SUBMITS NOTICE TO CALL A SPECIAL MEETING OF AMARIN SHAREHOLDERS TO
ADD DIRECTORS AND REMOVE CHAIRMAN PER WOLD-OLSEN
Sarissa believes current board lacks any remaining credibility for representing shareholders
Sarissa is astonished that Amarin board refuses to add shareholder representatives
Greenwich, CT, January 10, 2023 – Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):
At the last shareholder meeting, the shareholders, the owners of the company, loudly expressed their lack of faith in the board and management. Sarissa sought to place shareholder representatives on the board and engaged with the company in what turned out to be months of simply lip service by the board, led by its Chairman Per Wold-Olsen. Despite Sarissa having a track record of creating significant shareholder value in healthcare companies, including those with cardiovascular drugs such as The Medicines Company, Amarin’s board rejected adding any shareholder representatives to the board in favor of their own candidates, including today’s addition of a board candidate without any input from Sarissa, Amarin’s largest shareholder.
Amarin’s acknowledgement of its need for board refreshment is a positive step in recognizing the company’s many mishaps and the board’s own entrenchment. However, after months of back and forth, it is clear to us that this board refreshment process was a charade led by Chairman Per Wold-Olsen.
Sarissa is astounded by Amarin’s blatant disregard for shareholders. The board’s actions epitomize poor governance. We believe that they do not understand a board’s mission and duties to shareholders, the owners of the company. We can only conclude that Amarin’s board does not seek real change and instead wants to remain entrenched at the expense of shareholders.
Sarissa has submitted notice to Amarin under UK law to call a special meeting of shareholders to add 7 directors to the board and to remove Chairman Per Wold-Olsen from the board. In the event that the Amarin board attempts the contemptible act of continuing to entrench themselves by filling any of the vacancies on the board, takes any other actions in violation of their fiduciary duties or interferes with Sarissa’s exercise of its shareholder rights, Sarissa will initiate immediate legal action to hold all directors (including those added to the board) personally accountable to the fullest extent of the law. Such an act by the board would be the ultimate betrayal to shareholders. Sarissa will also seek to remove those directors appointed by the board in order to create the vacancies necessary to add Sarissa’s nominees to the board. We are asking all shareholders to remain engaged and voice their opinions by voting at the special meeting.

Contact:
Jean Puong
Sarissa Capital Management LP
info@sarissacap.com

###


CERTAIN INFORMATION CONCERNING THE PARTICIPANTS
Sarissa Capital Management LP (“Sarissa Capital”), together with the other participants named herein (collectively, “Sarissa”), intends to file a preliminary proxy statement and accompanying proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of highly-qualified nominees as directors of Amarin Corporation plc (NASDAQ: AMRN) (the “Company”), at a special meeting of shareholders of the Company. SARISSA STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR, THE IDENTITY AND CONTACT INFORMATION FOR WHICH WILL BE SET FORTH IN THE PROXY STATEMENT THAT WILL BE MADE AVAILABLE TO SHAREHOLDERS.
The participants in the proxy solicitation are anticipated to include Sarissa Capital, Sarissa Capital Offshore Master Fund LP (“Offshore”), Sarissa Capital Master Fund II LP (“Master II”), Sarissa Capital Athena Offshore Fund Ltd (“Athena”), Sarissa Capital Catapult Fund LLC (“Catapult”), Sarissa Capital Hawkeye Fund LP (“Hawkeye”), ISP Fund LP (“ISP”), Atom Master Fund LP (“Atom”), Sarissa Capital Management GP LLC (“Management GP”), Sarissa Capital Offshore Fund GP LLC (“Offshore GP”), Sarissa Capital Fund GP LP (“Fund GP LP”), Sarissa Capital Fund GP LLC (“Fund GP LLC”), Dr. Alexander J. Denner, Patrice Bonfiglio, Dr. Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III  and Diane E. Sullivan.
As of the date hereof and subject to the further explanatory information set forth in this paragraph, funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner may be deemed to beneficially own, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), 25,210,000 ordinary shares, par value 50 pence per share, of the Company (the “Shares”), as more fully described below. In addition, as of the date hereof, Mr. Sterling may be deemed to separately beneficially own, within the meaning of Rule 13d-3 under the Exchange Act, 117,772 Shares. Given Mr. Sterling’s beneficial ownership of Shares, he and the funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner may be deemed to have formed a group within the meaning of Rule 13d-5(b) under the Exchange Act. The number of Shares stated herein that may be deemed to be beneficially owned by Mr. Sterling does not include Shares that may be deemed to be beneficially owned by such funds and other investment vehicles, and the number of Shares stated herein that may be deemed to be beneficially owned by such funds and other investment vehicles does not include Shares that may be deemed to be beneficially owned by Mr. Sterling. Subject to the preceding sentence, as of the date hereof, the number of Shares that may be deemed to be beneficially owned, within the meaning of Rule 13d-3 under the Exchange Act, by funds and other investment vehicles affiliated with Sarissa Capital and Dr. Denner is as follows:

Sarissa Capital
25,210,000
Offshore
6,188,100
Master II
342,600
Athena
3,164,000
Catapult
4,298,200
Hawkeye
3,928,800
ISP
6,663,377
Atom
624,923
Management GP
25,210,000
Offshore GP
9,694,700
Fund GP LP
17,921,700
Fund GP LLC
17,921,700
Dr. Denner
25,210,000






EXHIBIT 6

JOINT FILING AGREEMENT

In accordance with Rule 13d−1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Ordinary Shares of Amarin Corporation plc and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein or therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement.

Dated: January 10, 2023

SARISSA CAPITAL MANAGEMENT LP


By: /s/ Mark DiPaolo _______________
 Name: Mark DiPaolo
 Title: Senior Partner, General Counsel


/s/ Alexander J. Denner                                  
Alexander J. Denner


/s/ Louis Sterling III                                       
Louis Sterling III
EXHIBIT 7

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS THAT the undersigned hereby constitutes and appoints Mark DiPaolo and Patrice Bonfiglio and each of them severally, as the true and lawful attorneys and agents of the undersigned, with power to act with or without the others and with full power of substitution and resubstitution, to execute in the name, place and stead of the undersigned any statement or report, including any amendment to any statement or report, required to be filed with respect to the undersigned with respect to Amarin Corporation plc under Section 13 or Section 16 of the United States Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements thereunder, including any forms or statements required to be submitted in connection with any electronic filing, or any statement or report, including any amendment to any statement or report, required to be filed with respect to the undersigned under any comparable laws, rules, regulations and requirements of any foreign jurisdiction, and to file any of the same with the Securities and Exchange Commission and any other appropriate U.S. and foreign regulatory authorities, said attorneys and agents having full power and authority to do and perform in the name and on behalf of the undersigned every act necessary to be done in the premises as fully and as effectually as the undersigned might or could do in person, and the undersigned hereby ratifies and confirms all that said attorneys and agents shall do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has subscribed these presents as of January 10, 2023.
 
   
 
/s/ Louis Sterling III
 
Louis Sterling III